How many people get sepsis?
Every year, severe sepsis strikes more than a million Americans1. It’s been estimated that between 28 and 50 percent of these people die2—far more than the number of U.S. deaths from prostate cancer, breast cancer and AIDS combined.
The number of sepsis cases per year has been on the rise in the United States. This is likely due to a combination of factors, including increased awareness and tracking of the condition, an aging population, the increased longevity of people with chronic diseases, the spread of antibiotic-resistant organisms, an upsurge in invasive procedures and broader use of immunosuppressive and chemotherapeutic agents.
"The PCSK9 effect was abrogated in LDL receptor (LDLR) knockout mice and in humans who are homozygous for an LDLR variant that is resistant to PCSK9. Together, our results show that reduced PCSK9 function is associated with increased pathogen lipid clearance via the LDLR, a decreased inflammatory response, and improved septic shock outcome."
"Human PCSK9 loss-of-function genetic variants were associated with improved survival in septic shock patients and a decrease in inflammatory cytokine response both in septic shock patients and in healthy volunteers after LPS administration."
"uch as lipopolysaccharide (LPS). Compared to controls, Pcsk9 knockout mice displayed decreases in inflammatory cytokine production and in other physiological responses to LPS. In human liver cells, PCSK9 inhibited LPS uptake, a necessary step in systemic clearance and detoxification. Pharmacological inhibition of PCSK9 improved survival and inflammation in murine polymicrobial peritonitis. "
"A decrease in the activity of proprotein convertase subtilisin/kexin type 9 (PCSK9) increases the amount of low-density lipoprotein (LDL) receptors on liver cells and, therefore, LDL clearance. The clearance of lipids from pathogens is related to endogenous lipid clearance; thus, PCSK9 may also regulate removal of pathogen lipids"
So many applications!!!
Google article title if interested, "New customer service robot roaming Indianapolis International Airport terminal"
Google article title if interested, "Willamette Valley wineries reaping record-setting harvest"
P.P.S. It wasn't referencing WVVI, it was referencing multiple vintners FROM the Willamette Valley. Don't worry, you're still a funny guy. LOL :-)
Remember, keep poping those pills. and "have a nice day"
Glad to see your still taking your meds, and maintaining that positive disposition. LOL :-)
As always, "have a nice day"
Google article title if interested, "Lawsuits: Dealership Commentator"
"We can keep Tesla busy defending what are basically nuisance suits.
But it will prevail in all states one at a time. Or there will be some sort of sweeping federal action in its favor."
Google article title if interested in complete arcticle, "Regeneron says allergy drug may be darling of its pipeline"
"REGN has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.
The allergy drug, dupilumab, is meant to treat underlying causes of asthma, eczema and nasal polyps and could transform treatment of those suspected related ailments, the officials say.
"We have a lot of debate within the company as to which of our many programs is the most exciting, and a lot of people are voting on dupilumab," Regeneron research chief George Yancopoulos said in an interview at company headquarters.
The other contender is a new type of cholesterol treatment, called alirocumab, which Regeneron expects to submit for regulatory approval later this year."